Furthermore, anti-inflammatory treatment with the corticosteroid-dexamethasone was associated with enhanced cellular effector response towards bacterial challenge, reduction of inflammatory mediators in the plasma as well as the reduction in CRP, IL-6 levels, length of ICU stay and ventilation-days in critically ill COVID-19 patients. Here, IL6 is linked to COVID-19.